Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression

  • Adam E Handel1, 2Email author,

    Affiliated with

    • Geir K Sandve3,

      Affiliated with

      • Giulio Disanto1,

        Affiliated with

        • Lahiru Handunnetthi1,

          Affiliated with

          • Gavin Giovannoni2 and

            Affiliated with

            • Sreeram V Ramagopalan1, 2

              Affiliated with

              BMC Medical Genomics20136:45

              DOI: 10.1186/1755-8794-6-45

              Received: 31 May 2013

              Accepted: 23 October 2013

              Published: 30 October 2013

              Abstract

              Background

              A wealth of nuclear receptor binding data has been generated by the application of chromatin immunoprecipitation (ChIP) techniques. However, there have been relatively few attempts to apply these datasets to human complex disease or traits.

              Methods

              We integrated multiple oestrogen receptor alpha (ESR1) ChIP datasets in the Genomic Hyperbrowser. We analysed these datasets for overlap with DNase I hypersensitivity peaks, differentially expressed genes with estradiol treatment and regions near single nucleotide polymorphisms associated with sex-related diseases and traits. We used FIMO to scan ESR1 binding sites for classical ESR1 binding motifs drawn from the JASPAR database.

              Results

              We found that binding sites present in multiple datasets were enriched for classical ESR1 binding motifs, DNase I hypersensitivity peaks and differentially expressed genes after estradiol treatment compared with those present in only few datasets. There was significant enrichment of ESR1 binding present in multiple datasets near genomic regions associated with breast cancer (7.45-fold, p = 0.001), height (2.45-fold, p = 0.002), multiple sclerosis (5.97-fold, p < 0.0002) and prostate cancer (4.47-fold, p = 0.0008), and suggestive evidence of ESR1 enrichment for regions associated with coronary artery disease, ovarian cancer, Parkinson’s disease, polycystic ovarian syndrome and testicular cancer. Integration of multiple cell line ESR1 ChIP datasets also increases overlap with ESR1 ChIP-seq peaks from primary cancer samples, further supporting this approach as helpful in identifying true positive ESR1 binding sites in cell line systems.

              Conclusions

              Our study suggests that integration of multiple ChIP datasets can highlight binding sites likely to be of particular biological importance and can provide important insights into understanding human health and disease. However, it also highlights the high number of likely false positive binding sites in ChIP datasets drawn from cell lines and illustrates the importance of considering multiple independent experiments together.

              Background

              Many diseases are typified by an unequal prevalence in females and males [1]. This gender disparity is particularly marked for autoimmune diseases, especially multiple sclerosis (MS) where the gender ratio is 2–3:1 [2, 3]. Coronary artery disease (CAD) has a lower frequency in premenopausal women and male gender is associated with higher mortality [1, 4]. Parkinson’s disease (PD) is more frequent amongst males than females [5]. Clearly certain diseases are either almost or completely gender-specific, such as gynaecological, testicular and prostate cancer.

              Much molecular work has focussed upon potential mechanisms underlying gender disparity observed in many of the above diseases. In autoimmunity, oestrogen has been shown to inhibit T-cell expansion and, in MS, alters T-cell proliferation and cytokine secretion in response to neutrally-derived antigens [69]. Oestrogen also has been shown to promote neuronal survival in neurodegenerative and neuroinflammatory conditions, including PD and MS [1012]. The cardioprotective effects of oestrogen are well-described and are thought to be mediated by vasodilatation and decreased atherosclerosis [13]. Oestrogen receptor alpha (ESR1) is required for the vasoprotective effects of oestrogen [14]. Oestrogen replacement therapy has a well-described association with gynaecological malignancy [15]. Differential ESR1 binding is associated with outcome following breast cancer and altered ESR1 expression in ovarian cancer is associated with prognosis [16, 17]. A role for oestrogen in testicular and prostate cancer has also been recognised [1821].

              Chromatin immunoprecipitation with chip hybridisation (ChIP-chip) or with massively parallel sequencing (ChIP-seq) has generated a vast amount of data in multiple different cell types regarding ESR1 binding across the genome. Combining ESR1 ChIP-seq datasets have provided insights into enhancer activity [22, 23]. There is great potential from combining transcription factor ChIP-seq or epigenomics to provide insights into disease pathophysiology [24]. Previous studies have revealed enrichment for disease-associated variants with markers of open chromatin and disease-relevant transcription factor binding sites [2528].

              We aimed to analyse whether ESR1 binding is enriched in regions associated with diseases and traits that show marked gender disparity and to what extent biologically important information can be obtained by combining ChIP-chip/-seq data obtained by different methodologies. Our study differs from previous attempts to integrate ESR1 ChIP studies by assessing the degree to which useful information can be obtained regardless of specific methodology used. Our hope is that our findings may allow further functional work to focus on candidate variants likely to be important in diseases or traits showing sexual disparity. It is also likely that many ESR1 ChIP peaks are false positives and we aimed to assess whether overlap between different ChIP datasets may enable identification of peaks that are more likely to be true positive binding sites [29].

              Methods

              ChIP-chip/-seq data

              We included 15 ESR1 ChIP-chip/-seq datasets where cells had been stimulated with estradiol prior to ChIP from Cistrome and Medline [3042]. We also included ESR1 ChIP-seq peaks common to all primary cancer cell samples from breast cancer patients [16]. The characteristics of these studies are shown in Additional file 1: Table S1.

              Motif analysis

              De novo motif discovery was undertaken using MEME-ChIP searching the central 200 bases within each binding interval for either one or no motif per site between 6 and 30 bases in length [43]. STAMP was used to analyse motifs generated by MEME-ChIP for similarity between different datasets using the settings “Metric = PCC, Alignment = SWU, Gap-open = 1000, Gap-extend = 1000,-nooverlapalign Multiple Alignment = IR, Tree = UPGMA, Matching against: user-defined” [44]. The central 200 basepairs of each binding site and the region within 20 bases of SNPs either associated with disease or in linkage disequilibrium with r2 ≤ 0.8 were scanned for JASPAR 2009 ESR1 binding motif (MA0112.2) occurrences with p ≤ 0.0001 using FIMO [45].

              ESR1 enrichment within disease/trait-associated genomic regions and hierarchal clustering analysis

              The Genomic HyperBrowser was used to determine overlap and hierarchical clustering between different datasets [46, 47]. Tracks comprising different genomic features are annotated as segments, which are different stretches of specific chromosomes, or points, which are basepair locations on specific chromosomes. We defined disease-associated genomic regions as those within 100 kb of SNPs in the Genome Wide Association Study Catalogue (downloaded on 30/03/2013) with a p-value ≤1×10-7 for pre-defined conditions/traits with known gender disparity (androgen levels, estradiol levels, breast cancer, coronary heart disease, height, male baldness, menopause, menarche, migraine, multiple sclerosis, ovarian cancer, Parkinson’s disease, polycystic ovarian syndrome, prostate cancer, sex hormone binding globulin levels and testicular cancer) in a similar manner to a previous study [48, 49]. Overlap was determined using segment-segment analysis with 10,000 Monte-Carlo randomisations maintaining the empiric distribution of segment and inter-segment lengths, but randomising positions. We generated an intensity track based on the proximity of all ESR1 binding sites to the nearest gene. ESR1 binding intervals were represented as points (midpoints of ESR1 binding peaks) and a point-segment analysis using 1,000 Monte-Carlo randomisations with points sampled according to the intensity track, were used to compute p-values (disease/trait-associated regions were represented as segments as before). Hierarchical clustering analysis was performed in the Genomic HyperBrowser by obtaining pairwise overlap-enrichment values for each of the samples and computing distance between samples as the inverse of these values. DNase I hypersensitivity peaks were obtained from UCSC Table Browser [50] and GRO-seq data on differentially expressed genes with estradiol treatment (q ≤ 0.001 for at least one timepoint) from [51]. The midpoint of ESR1 binding sites were classified as falling within exons, introns, UTR, up-/down-/up&down-stream (5 kb) or intergenic regions relative to RefSeq genes.

              Results

              ESR1 binding sites in different datasets

              The characteristics of each study are shown in Additional file 1: Table S1. Overall, between the 15 datasets, 127,193 ESR1 binding sites were identified. 89,964 (70.7%) were unique to a single dataset, 19,833 (15.6%) were common to at least 3 datasets, 8,390 (6.6%) to at least 5 datasets, 2,880 (2.3%) to at least 8 datasets and 897 (0.7%) to at least 11 datasets. Even when restricting analysis to only those studies conducted in MCF-7 cells exposed to estradiol for 45 minutes, 69.1% of binding sites were unique to a single dataset. Certain regions of the genome are known to generate false positive ChIP-seq peaks, however, only a minority of ESR1 binding sites are located within these regions, and none which are common to highly shared binding sites (Additional file 1: Table S2) [52]. The genomic distribution of ESR1 binding sites was similar regardless of the shared number of datasets (Additional file 1: Table S3). In 12 datasets, the top motif identified by MEME was highly similar to the consensus ESR1 motif on JASPAR 2009 [53] (Additional file 2: Figure S1). The motifs in those 12 showed significant similarity with one another when analysed in STAMP, as did motifs detected in the remaining three, although these were of uncertain biological significance. In all datasets, DREME identified motifs showing significant similarity to ESR1 motifs (Additional file 3: Figure S2). Motif analysis conducted on intervals shared between datasets is shown in Figure 1. In each case, the top motif identified showed significant similarity to the consensus ESR1 motif. The presence of a JASPAR 2009 consensus ESR1 motif (at p ≤ 0.0001) was significantly correlated with the number of shared datasets for each binding site from 13.7% of binding sites unique to a single dataset to 46.3% of those shared between all 15 datasets (r2 = 0.71, p = 0.0008, Additional file 1: Table S4). We conducted MEME and DREME analysis in those ESR1 ChIP-seq peaks shared between at least 5 datasets that were found to lack a classical ESR1 recognition motif. MEME was unable to identify any ESR1-like motifs but did identify an SP1-like motif (Additional file 4: Figure S3). The top DREME motif was a FOXA1 binding motif and the second was a partial ESR1/2 motif, suggesting that in some binding intervals lacking the classical ESR1 recognition motif, ESR1 may interact with a degenerate motif. FOXA1 has been described as a binding partner of ESR1 in previous studies and is involved in chromatin interactions [54]. Interestingly MEME and DREME did not identify any FOXA1-like motif in ChIP-seq peaks containing ESR1 classical motifs but did identify similar SP1-like motifs. Hierarchical clustering analysis showed that the ESR1 ChIP datasets conducted in cells derived from uterine tissue cluster together but there was no other obvious clustering based on either the type of breast cancer cells or the length of estradiol treatment used (Figure 2). Only two studies explicitly detailed the use of more than one biological replicates per treatment condition (Carroll et al.[30] and Hurtado et al.[31]) and there was a trend towards a lower proportion of ESR1 ChIP-seq peaks being unique to a single dataset in these (r2 = 0.19, p = 0.054) and a higher proportion of highly shared peaks, which reached significance in those shared between 8 and 10 datasets (8 datasets: r2 = 0.27, p = 0.02; 9 datasets: r2 = 0.25, p = 0.03 and 10 datasets r2 = 0.21, p = 0.04).
              http://static-content.springer.com/image/art%3A10.1186%2F1755-8794-6-45/MediaObjects/12920_2013_420_Fig1_HTML.jpg
              Figure 1

              MEME-identified motifs within ESR1 binding sites in common between datasets. E-values are shown for each motif along with TOMTOM similarity to known motifs (JASPAR (upper case) and uniprobe mouse (lower case) with E-value <10).

              http://static-content.springer.com/image/art%3A10.1186%2F1755-8794-6-45/MediaObjects/12920_2013_420_Fig2_HTML.jpg
              Figure 2

              Hierarchical clustering of ESR1 binding sites between different datasets. (A) A dendrogram and heatmap of genomic binding illustrating clustering between different datasets. (B) A heat map showing relative distances between pairs of datasets (red = 0.000 to dark green = 0.036; units are the inverse of pairwise overlap between ChIP datasets). Study details show the first author, tissue type, cell type and length of estradiol treatment.

              ESR1 enrichment within disease/trait-associated regions

              There was highly significant enrichment of ESR1 binding sites within genomic regions associated with breast cancer, height, MS and prostate cancer, which was consistent over multiple datasets and increased in magnitude for binding sites shared between multiple datasets (Additional file 1: Table S5, Table 1). There was suggestive enrichment for CAD, ovarian cancer, Parkinson’s disease, polycystic ovarian syndrome and testicular cancer, although these were not consistent findings across all datasets. ESR1 binding site enrichment within disease/trait-associated regions remained significant when controlling for the position of genes. We also assessed disease/trait overlap using the central 200 bases of each binding site to control for differing size of binding sites and found very similar results (Additional file 1: Table S6). 645 SNPs either directly associated with diseases/traits or in strong linkage disequilibrium (r2 ≥ 0.8) were located within ESR1 binding sites but only 12 of these directly disrupted a classical ESR1 recognition motif (Additional file 1: Table S7).
              Table 1

              Enrichment of ESR1 binding sites within genomic regions associated with diseases or traits from GWAS

              GWAS disease/trait

              All ESR1

              ESR1 in ≥3 datasets

              ESR1 in ≥5 datasets

              ESR1 in ≥8 datasets

              ESR1 in ≥11 datasets

               

              O/E

              p

              O/E

              p

              O/E

              p

              O/E

              p

              O/E

              p

              Androgen levels

              1.02

              0.8857

              0.75

              0.8063

              0.67

              0.9093

              1.60

              0.4880

              4.47

              0.1062

              Estradiol levels

              1.67

              0.8659

              1.21

              0.7437

              1.06

              0.8905

              1.82

              0.6311

              0.00

              1.0000

              Breast cancer

              2.09

              0.0002

              3.21

              0.0004

              3.92

              0.0012

              5.98

              0.0038

              7.45

              0.0012

              (0.002)

               

              (0.002)

               

              (0.002)

               

              (0.002)

               

              (0.002)

              Coronary artery disease

              1.43

              0.0002

              1.69

              0.0068

              1.74

              0.0270

              1.90

              0.0704

              0.49

              0.4322

              (0.002)

               

              (0.002)

               

              (0.005)

                  

              Height

              1.55

              0.0002

              1.77

              0.0002

              1.87

              0.0004

              2.36

              0.0012

              2.45

              0.0018

              (0.002)

               

              (0.002)

               

              (0.002)

               

              (0.004)

               

              (0.004)

              Male baldness

              0.75

              0.1652

              0.42

              0.1840

              0.37

              0.3384

              0.41

              0.7137

              1.16

              0.5043

              Menopause

              1.05

              0.8431

              0.89

              0.7393

              0.67

              0.4668

              0.59

              0.5813

              0.64

              0.9471

              Menarche

              1.11

              0.4504

              1.20

              0.5341

              1.30

              0.4410

              1.60

              0.2680

              1.07

              0.9173

              Migraine

              1.29

              0.2036

              1.55

              0.2554

              2.42

              0.0618

              1.32

              0.6031

              0.00

              1.0000

              Multiple sclerosis

              2.98

              0.0002

              2.98

              0.0002

              3.40

              0.0002

              4.22

              0.0008

              5.97

              0.0002

              (0.002)

               

              (0.002)

               

              (0.002)

               

              (0.002)

               

              (0.047)

              Ovarian cancer

              1.79

              0.0134

              1.93

              0.2676

              2.64

              0.1596

              3.61

              0.1564

              0.00

              1.0000

              (0.002)

                      

              Parkinson’s disease

              1.54

              0.0228

              1.65

              0.2158

              1.62

              0.3910

              1.17

              0.9067

              1.35

              0.9077

              (0.002)

                      

              Polycystic ovarian syndrome

              2.42

              0.0002

              3.60

              0.0038

              2.20

              0.3386

              1.79

              0.6467

              3.21

              0.3286

              (0.002)

               

              (0.022)

                    

              Prostate cancer

              1.82

              0.0002

              2.40

              0.0002

              2.62

              0.0006

              2.76

              0.0168

              4.47

              0.0008

              (0.002)

               

              (0.002)

               

              (0.002)

               

              (0.002)

               

              (0.002)

              Sex hormone binding globulin levels

              1.09

              0.8553

              0.70

              0.4008

              0.46

              0.2856

              0.29

              0.3958

              0.00

              1.0000

              Testicular cancer

              1.52

              0.0056

              1.36

              0.3218

              0.57

              0.7883

              0.92

              0.7523

              2.59

              0.1498

                

              (0.002)

                      

              Enrichment is shown by differing numbers of shared datasets. Significant enrichment is highlighted in bold and the p-value corrected for genomic location of genes is shown in parenthesis after nominally significant enrichments. O/E = observed/expected ratio.

              DNase I hypersensitivity peaks, gene expression and ESR1 binding

              ESR1 binding sites were significantly enriched for DNaseI hypersensitivity peaks drawn from multiple cell types (Ecc-1, Ishikawa, MDF-7, T47D, LNCaP, HUVEC, glioma and Th1 CD4+, Additional file 1: Table S8). Interestingly, for all apart from Th1 CD4+ cells (r2 = 0.05, p = 0.41), HUVEC (r2 = 0.002, p = 0.86) and glioblastoma (r2 = 0.05, p = 0.41), there was a significant correlation between the number of shared datasets at each ESR1 binding site and the enrichment for DNase I hypersensitivity peaks (Ecc-1 r2 = 0.75, p < 0.0001; Ishikawa r2 = 0.70, p < 0.0001; MCF7 r2 = 0.67, p = 0.0002; T47D plus estradiol r2 = 0.97, p < 0.0001; T47D r2 = 0.82, p < 0.0001; and LNCaP r2 = 0.61, p = 0.0006; Figure 3). This relationship was maintained when ESR1 binding sites were trimmed to the central 200 basepairs to control for differing binding site lengths. ESR1 binding in regions associated with MS were highly enriched for Th1 CD4+ DNase I hypersensitivity peaks (7.41-fold, p < 0.0002) and those in regions associated with prostate cancer for LNCaP DNase I hypersensitivity peaks (9.39-fold, p < 0.0002).
              http://static-content.springer.com/image/art%3A10.1186%2F1755-8794-6-45/MediaObjects/12920_2013_420_Fig3_HTML.jpg
              Figure 3

              Enrichment of ESR1 binding sites within DNase I hypersensitivity peaks. Different cell types are shown as different series where E2 = estradiol-treated.

              There was significant enrichment of ESR1 binding sites with 5 kb of genes differentially expressed following estradiol treatment (Additional file 1: Table S8) [51]. The degree of enrichment was highly correlated with the number of shared datasets for each ESR1 binding site (r2 = 0.89, p < 0.0001), which again was unaffected by restricting analysis to only the central 200 basepairs of each binding interval (r2 = 0.94, p < 0.0001).

              Biological significance of motif/DNase I hypersensitivity

              We divided ESR1 binding sites into those with and without ESR1 classical motifs. There was some evidence that binding sites with a motif present were more frequently located near disease/trait-associated regions than those without in (breast cancer, coronary artery disease, height, Parkinson’s disease and prostate cancer) but this was not true for all diseases/traits (Additional file 1: Table S9). Motif-containing binding sites were consistently more enriched for DNase I hypersensitivity peaks in all cell types and within 5 kb of genes expressed differently with estradiol treatment than those without motifs.

              We also separated ESR1 binding sites into those overlapping and not overlapping DNase I hypersensitivity peaks. Disease/trait-associated regions were highly enriched for DNase I hypersensitivity peaks (Figure 4; Additional file 1: Table S9). Motif analysis on ESR1 binding sites overlapping and not overlapping DNase I hypersensitivity peaks common to at least 5 datasets showed ESR1 recognition motifs as the top motif in both cases. Similarly, in both cases motifs similar to FOXA1 were identified.
              http://static-content.springer.com/image/art%3A10.1186%2F1755-8794-6-45/MediaObjects/12920_2013_420_Fig4_HTML.jpg
              Figure 4

              Enrichment of ESR1 binding sites overlapping and not overlapping DNase I hypersensitivity peaks within disease/trait-associated regions. ESR1 binding sites are divided into those overlapping and not overlapping DNase I hypersensitivity peaks in the MCF7 breast cancer cell line.

              Primary cancer ESR1 ChIP-seq

              It is possible that the ESR1 ChIP overlap findings are biased by being conducted in cell lines. We analysed ESR1 ChIP-seq data drawn from primary breast cancer samples in relation to GWAS disease/trait regions, DNase I hypersensitivity peaks and estradiol-induced gene expression (Additional file 1: Table S10) [16]. There was significant enrichment of ESR1 binding in GWAS regions associated with androgen levels (11.76-fold, p = 0.02) and breast cancer (11.76-fold, p = 0.0008) with trends for several other conditions/traits. There was highly significant enrichment of ESR1 binding within DNase I hypersensitivity peaks from all cell types studied and near genes differentially expressed with estradiol treatment.

              There was a strong correlation between ESR1 ChIP-seq peaks in primary cancer samples and the number of shared datasets for each ESR1 binding site in cell lines (r2 = 0.74, p < 0.0001), which was preserved when restricting analysis to only the central 200 basepairs of each ESR1 binding site (r2 = 0.73, p < 0.0001).

              Discussion

              There is huge variation between individual ESR1 ChIP experiments with most binding sites unique to a single experiment. This may stem from the frequent use of immortalised cell lines, which are known to accrue mutations on prolonged culture and thus may generate a large number of false positive binding sites [55, 56]. ESR1 binding sites shared between multiple experiments are likely to be more important to regulatory activity given the higher enrichment of DNase I hypersensitivity peaks, differentially expressed genes and ESR1 binding motifs at highly shared sites compared with sites shared only between few experiments. This is supported by increased enrichment of ESR1 binding sites near regions associated with diseases/traits when those binding sites contain motifs or DNase I hypersensitivity peaks. This suggests that integrating multiple different published ChIP datasets is important in mapping the most important binding sites for transcription factors and can provide valuable biological insights even if the precise methodologies used in each experiment differ [22]. Our analysis thus suggests that integration of multiple ChIP datasets, especially in cell lines, is important to distinguish true positive from false positive ChIP peaks. This is supported by far higher overlap of ESR1 ChIP-seq peaks in primary cancer cells with cell line ChIP peaks found in multiple datasets. Our results also emphasise the importance of analysing biological replicates. However, one key limitation of ChIP-seq from primary cell lines is that, due to the more differentiated nature of primary cells, nuclear factor binding is less likely to be informative of overlap with susceptibility regions in diseases not primarily affecting that tissue type. Further work will be needed to reveal whether similar relationships between biological importance and preservation of ChIP peaks in multiple datasets exists for other nuclear receptors and transcription factors. This also underlines the importance of uploading raw data on all ChIP experiments so that datasets can be directly compared by calling peaks in the same manner.

              Interestingly, ESR1 ChIP peaks identified in breast or uterine cell lines also show significant enrichment for DNase I hypersensitivity peaks from other cell lines, which suggests that functional annotation of the genome may be able to cast some light even on biological pathways in cell lines far removed from the ChIP-seq material. This makes the ENCODE approach a very powerful one, since functional genomics data could potentially be used to generate powerful hypotheses about biological systems removed from the particular one used in an individual experiment [57].

              We found that ESR1 binding sites were strongly enriched near regions associated with susceptibility to breast cancer, height, MS and prostate cancer, suggesting that ESR1 may contribute to the functional genomics of these diseases. We have shown that susceptibility SNPs frequently fall beneath ESR1 ChIP peaks and thus suggest a possible functional basis for several GWAS susceptibility SNPs. Some of these were supported by ESR1 ChIP-seq peaks derived from primary cancer samples but this is likely limited by the small number of binding sites in common between samples and the relatively differentiated nature of the chromatin architecture compared with cell lines. Further work should concentrate on integrating expression data with known ESR1 ChIP-seq peaks in order to dissect out the precise details of this interaction between ESR1 binding and disease susceptibility. Focussing on the variants highlighted in our analysis for further functional studies may provide direct evidence of disease susceptibility variants affecting ESR1 binding. ESR1 is an attractive candidate, the binding of which may underlie several diseases showing marked gender disparity. This may ultimately permit the identification of novel biochemical pathways that provide new therapeutic targets [58].

              Conclusions

              We have shown that integration of ChIP datasets drawn from multiple different cell lines is a powerful technique to screen out false positive nuclear factor binding sites. Moreover, ESR1 binding sites present in multiple experiments were enriched for ESR1 ChIP-seq peaks from primary cancer samples, DNase I hypersensitivity regions, genes differentially expressed after exposure to estradiol, and regions associated with diseases and traits characterised by sexual disparity. Future work should attempt to use primary cells whenever possible and should focus on potential functional variants that may be linked with human phenotypes identified in this study.

              Declarations

              Funding

              This work was supported by the Medical Research Council. AEH was supported by an NIHR Academic Clinical Fellowship and a Wellcome Trust Research Training Fellowship.

              Authors’ Affiliations

              (1)
              Medical Research Council Functional Genomics Unit and Department of Physiology, Anatomy and Genetics, University of Oxford
              (2)
              Barts and The London School of Medicine and Dentistry, Blizard Institute, Queen Mary University of London
              (3)
              Department of Informatics, University of Oslo

              References

              1. Pinkhasov RM, Shteynshlyuger A, Hakimian P, Lindsay GK, Samadi DB, Shabsigh R: Are men short-changed on health? Perspective on life expectancy, morbidity, and mortality in men and women in the United States. Int J Clin Pract 2010, 64:465–474.PubMedView Article
              2. Orton S-M, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006, 5:932–936.PubMedView Article
              3. Moroni L, Bianchi I, Lleo A: Geoepidemiology, gender and autoimmune disease. Autoimmun Rev 2012, 11:A386-A392.PubMedView Article
              4. Shaw LJ, Shaw RE, Merz CNB, Brindis RG, Klein LW, Nallamothu B, Douglas PS, Krone RJ, McKay CR, Block PC, Hewitt K, Weintraub WS, Peterson ED: Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008, 117:1787–1801.PubMedView Article
              5. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J: Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatr 2004, 75:637–639.PubMedView Article
              6. Adori M, Kiss E, Barad Z, Barabás K, Kiszely E, Schneider A, Kövesdi D, Sziksz E, Abrahám IM, Matkó J, Sármay G: Estrogen augments the T cell-dependent but not the T-independent immune response. Cell Mol Life Sci 2010, 67:1661–1674.PubMedView Article
              7. Michalek RD, Gerriets VA, Nichols AG, Inoue M, Kazmin D, Chang C-Y, Dwyer MA, Nelson ER, Pollizzi KN, Ilkayeva O, Giguere V, Zuercher WJ, Powell JD, Shinohara ML, McDonnell DP, Rathmell JC: Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci USA 2011, 108:18348–18353.PubMedView Article
              8. Gilmore W, Weiner LP, Correale J: Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 1997, 158:446–451.PubMed
              9. Correale J, Ysrraelit MC, Gaitán MI: Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol 2010, 185:4948–4958.PubMedView Article
              10. Baudry M, Bi X, Aguirre C: Progesterone-estrogen interactions in synaptic plasticity and neuroprotection. Neuroscience 2012, 239:280–294.PubMedView Article
              11. Kipp M, Amor S, Krauth R, Beyer C: Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender. Front Neuroendocrinol 2012, 33:1–16.PubMedView Article
              12. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL: Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. Brain 2012,135(Pt 1):124–138.PubMedView Article
              13. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801–1811.PubMedView Article
              14. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME: Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002, 90:1087–1092.PubMedView Article
              15. International Menopause Society Expert Workshop: Hormone replacement therapy and cancer. Gynecol Endocrinol 2001, 15:453–465.
              16. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin S-F, Palmieri C, Caldas C, Carroll JS: Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389–393.PubMed
              17. Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M, Dietel M, Lage H, Surowiak P: Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 2011, 17:511–518.PubMedView Article
              18. Nakamura Y, McNamara K, Sasano H: Estrogen receptor expression and its relevant signaling pathway in prostate cancer: a target of therapy. Curr Mol Pharmacol 2013. Published ahead of print
              19. Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA, Stanford JL: Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate 2013, 73:1–10.PubMedView Article
              20. Brokken LJS, Lundberg-Giwercman Y, De-Meyts ER, Eberhard J, Ståhl O, Cohn-Cedermark G, Daugaard G, Arver S, Giwercman A: Association of polymorphisms in genes encoding hormone receptors ESR1, ESR2 and LHCGR with the risk and clinical features of testicular germ cell cancer. Mol Cell Endocrinol 2012, 351:279–285.PubMedView Article
              21. Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC, Foresta C: Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr Relat Cancer 2010, 17:17–25.PubMedView Article
              22. Welboren W-J, Sweep FCGJ, Span PN, Stunnenberg HG: Genomic actions of estrogen receptor α: what are the targets and how are they regulated? Endocr Relat Cancer 2009, 16:1073–1089.PubMedView Article
              23. Hah N, Murakami S, Nagari A, Danko CG, Kraus WL: Enhancer transcripts mark active estrogen receptor binding sites. Genome Res 2013, 23:1210–1223.PubMedView Article
              24. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M: Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012, 22:1790–1797.PubMedView Article
              25. Trynka G, Sandor C, Han B, Xu H, Stranger BE, Liu XS, Raychaudhuri S: Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 2013, 45:124–130.PubMedView Article
              26. Ding M, Wang H, Chen J, Shen B, Xu Z: Identification and functional annotation of genome-wide ER-regulated genes in breast cancer based on ChIP-Seq data. Comput Math Methods Med 2012, 2012:568950.PubMed
              27. Wang C, Sandling JK, Hagberg N, Berggren O, Sigurdsson S, Karlberg O, Rönnblom L, Eloranta M-L, Syvänen A-C: Genome-wide profiling of target genes for the systemic lupus erythematosus-associated transcription factors IRF5 and STAT4. Ann Rheum Dis 2013, 72:96–103.PubMedView Article
              28. Disanto G, Kjetil Sandve G, Ricigliano VAG, Pakpoor J, Berlanga-Taylor AJ, Handel AE, Kuhle J, Holden L, Watson CT, Giovannoni G, Handunnetthi L, Ramagopalan SV: DNase hypersensitive sites and association with multiple sclerosis. Hum Mol Genet 2013. Published ahead of print
              29. Vinckevicius A, Chakravarti D: Chromatin immunoprecipitation: advancing analysis of nuclear hormone signaling. J Mol Endocrinol 2012, 49:R113-R123.PubMedView Article
              30. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M: Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38:1289–1297.PubMedView Article
              31. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008, 456:663–666.PubMedView Article
              32. Hu M, Yu J, Taylor JMG, Chinnaiyan AM, Qin ZS: On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Res 2010, 38:2154–2167.PubMedView Article
              33. Welboren W-J, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG: ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 2009, 28:1418–1428.PubMedView Article
              34. Stender JD, Kim K, Charn TH, Komm B, Chang KCN, Kraus WL, Benner C, Glass CK, Katzenellenbogen BS: Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 2010, 30:3943–3955.PubMedView Article
              35. Schmidt D, Schwalie PC, Ross-Innes CS, Hurtado A, Brown GD, Carroll JS, Flicek P, Odom DT: A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 2010, 20:578–588.PubMedView Article
              36. Cicatiello L, Mutarelli M, Grober OMV, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M, Weisz A: Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 2010, 176:2113–2130.PubMedView Article
              37. Gu F, Hsu H-K, Hsu P-Y, Wu J, Ma Y, Parvin J, Huang TH-M, Jin VX: Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data. BMC Syst Biol 2010, 4:170.PubMedView Article
              38. Tsai W-W, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai C-Y, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung M-C, Patel DJ, Barton MC: TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010, 468:927–932.PubMedView Article
              39. Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, Pan YF, Li G, Lim M, Thomsen JS, Ruan Y, Clarke ND, Prabhakar S, Cheung E, Liu ET: Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol 2010, 6:456.PubMedView Article
              40. Hua S, Kittler R, White KP: Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 2009, 137:1259–1271.PubMedView Article
              41. Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G: Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. Mol Endocrinol 2012, 26:1941–1952.PubMedView Article
              42. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J, Lei Y, Pape UJ, Poidinger M, Chen Y, Yeung K, Brown M, Turpaz Y, Liu XS: Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol 2011, 12:R83.PubMedView Article
              43. Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, Ren J, Li WW, Noble WS: MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res 2009,37(Web Server issue):W202-W208.PubMedView Article
              44. Mahony S, Benos PV: STAMP: a web tool for exploring DNA-binding motif similarities. Nucleic Acids Res 2007,35(Web Server issue):W253-W258.PubMedView Article
              45. Grant CE, Bailey TL, Noble WS: FIMO: scanning for occurrences of a given motif. Bioinformatics 2011, 27:1017–1018.PubMedView Article
              46. Sandve GK, Gundersen S, Rydbeck H, Glad IK, Holden L, Holden M, Liestøl K, Clancy T, Ferkingstad E, Johansen M, Nygaard V, Tøstesen E, Frigessi A, Hovig E: The Genomic HyperBrowser: inferential genomics at the sequence level. Genome Biol 2010, 11:R121.PubMedView Article
              47. Gundersen S, Kalaš M, Abul O, Frigessi A, Hovig E, Sandve GK: Identifying elemental genomic track types and representing them uniformly. BMC Bioinforma 2011, 12:494.View Article
              48. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA: Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009, 106:9362–9367.PubMedView Article
              49. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, Handunnetthi L, Handel AE, Disanto G, Orton S-M, Watson CT, Morahan JM, Giovannoni G, Ponting CP, Ebers GC, Knight JC: A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010, 20:1352–1360.PubMedView Article
              50. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, Goldman M, Barber GP, Clawson H, Coelho A, Diekhans M, Dreszer TR, Giardine BM, Harte RA, Hillman-Jackson J, Hsu F, Kirkup V, Kuhn RM, Learned K, Li CH, Meyer LR, Pohl A, Raney BJ, Rosenbloom KR, Smith KE, Haussler D, Kent WJ: The UCSC Genome Browser database: update 2011. Nucleic Acids Res 2011,39(Database issue):D876-D882.PubMedView Article
              51. Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT, Kraus WL: A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 2011, 145:622–634.PubMedView Article
              52. Kundaje A: A comprehensive collection of signal artifact blacklist regions in the human genome. Encode https://​sites.​google.​com/​site/​anshulkundaje/​projects/​blacklists (last accessed 30/06/2013)
              53. Sandelin A, Wasserman WW: Constrained binding site diversity within families of transcription factors enhances pattern discovery bioinformatics. J Mol Biol 2004, 338:207–215.PubMedView Article
              54. Laganière J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguère V: From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 2005, 102:11651–11656.PubMedView Article
              55. Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998, 51:227–238.PubMedView Article
              56. Roy R, Chun J, Powell SN: BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012, 12:68–78.View Article
              57. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, Epstein CB, Frietze S, Harrow J, Kaul R, Khatun J, Lajoie BR, Landt SG, Lee B-K, Pauli F, Rosenbloom KR, Sabo P, Safi A, Sanyal A, Shoresh N, Simon JM, Song L, Trinklein ND, Altshuler RC, Birney E, Brown JB, Cheng C, Djebali S, Dong X, Dunham I, et al.: An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57–74.PubMedView Article
              58. Smith RP, Lam ET, Markova S, Yee SW, Ahituv N: Pharmacogene regulatory elements: from discovery to applications. Genome Med 2012, 4:45.PubMedView Article
              59. Pre-publication history

                1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1755-8794/​6/​45/​prepub

              Copyright

              © Handel et al.; licensee BioMed Central Ltd. 2013

              This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

              Advertisement